20/20 Biolabs, Inc develops and commercializes AI powered laboratory based blood tests for the early detection and prevention of cancers and chronic diseases. The company runs a CAP accredited CLIA licensed laboratory in Gaithersburg Maryland that also hosts the Clinical Laboratory Innovation Accelerator known as CLIAx. In addition to its blood test portfolio the company maintains a legacy business that sells a field test kit called BioCheck for screening suspicious powders for bioterror agents.

The company generates revenue from the sale of its blood tests and related laboratory services. Its primary product OneTest for Cancer is a multi cancer early detection test that accounted for approximately eighty eight percent of revenue in 2025 and eighty five percent in 2024. Another product OneTest for Longevity measures inflammatory biomarkers and was launched in February 2026 and is marketed both directly to consumers and to self insured employers under the brand OneTest for Workplace Wellness. The legacy BioCheck field test kit for screening suspicious powders contributed about eight percent of revenue in 2025 and ten percent in 2024. The Clinical Laboratory Innovation Accelerator CLIAx provides shared laboratory services to diagnostics start ups and represented roughly four percent of revenue in 2025 and five percent in 2024. Customers include fire departments occupational health providers retail clinics pharmacies and supermarkets such as Giant Food as well as employers veterans and individual consumers seeking preventive health screening.

The company operates through the following segments.

• OneTest for Cancer segment develops and sells AI powered multi cancer early detection blood tests that use protein tumor markers and algorithms to assess cancer risk.

• BioCheck segment provides a field test kit that screens suspicious powders for bioterror agents by detecting the presence of protein to enable rapid threat assessment for emergency responders.

• CLIAx segment operates a shared CLIA licensed laboratory that allows diagnostics start ups to validate and launch their tests using the company's equipment and personnel while generating service revenue and marketing rights.

The company positions itself as an affordable and accessible entrant in the multi cancer early detection market where most competitors rely on costly circulating tumor DNA sequencing. Its OneTest for Cancer is priced under two hundred dollars compared to the nine hundred fifty dollar list price of Grail's Galleri test and offers a top of the funnel approach that guides patients to lower cost follow up testing. Competitive advantages include the use of protein tumor markers that are detectable at earlier stages than circulating tumor DNA the ability to collect capillary blood without a phlebotomist and an AI algorithm that integrates biomarker levels with clinical factors to improve sensitivity. The company also benefits from its CLIA licensed laboratory and its Clinical Laboratory Innovation Accelerator which together provide a low cost platform for launching new tests. In the longevity space the company differentiates itself by combining inflammatory biomarker measurement with the Dietary Inflammatory Index and personalized dietary guidance a combination not widely offered by other labs.

The company serves a diverse customer base that includes fire departments occupational health providers retail clinics pharmacies and individual consumers. Specific named customers include the supermarket chain Giant Food and the retail clinic operator AnyLabTestNow which host the company's blood tests at their locations. In addition the company sells tests to employers veterans and patients seeking preventive health screening through direct to consumer and business to business channels.